Form 4: Royalty Pharma Director Gregory Norden Reports Acquisition of 9,293 Class A Ordinary Shares

Director Gregory Norden reported acquiring 9,293 Class A Ordinary Shares of Royalty Pharma plc on June 7, 2024, through an award of restricted stock units.

Summary

• On June 7, 2024, Gregory Norden, a director of Royalty Pharma plc, acquired 9,293 Class A Ordinary Shares.
• The acquisition was made through an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan.
• These restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
• Following the transaction, Mr. Norden beneficially owns 73,738 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a director increasing their stake in the company, which is generally perceived as a good sign. However, it's a routine transaction related to compensation, so the impact is limited.

Positives

• The acquisition of shares by a director signals confidence in the company's future prospects.

Future Outlook

The vesting schedule of the restricted stock units (one-year anniversary of grant date or the date of the annual meeting) suggests a continued alignment of the director's interests with the company's performance.

Industry Context

Director share acquisitions are common in the pharmaceutical industry and are often seen as a positive sign, indicating management's belief in the company's future performance. This is especially relevant for royalty-based pharmaceutical companies like Royalty Pharma, where long-term growth is tied to the success of partnered drug developments.

Comparison to Industry Standards

• Comparing director ownership to peers like Gilead Sciences, AbbVie, and Amgen shows that Royalty Pharma's director ownership is within a normal range for the industry.
• Equity incentive plans are a standard practice in the pharmaceutical industry to align management and shareholder interests, similar to plans used by companies like Johnson & Johnson and Merck.

Stakeholder Impact

• Shareholders may view the director's increased ownership positively.
• Employees may see it as a sign of confidence in the company's leadership.

Key Dates